Metabolic Changes After Bariatric Surgery

Summary

Literature data clearly demonstrate that treatment of obese patients is very expensive, long and achieve weight loss may not be permanent, and regardless of whether the treatment dominated diet therapy, physical activity, or pharmacotherapy. Experience of the last decade has shown that after surgical interventional treatment of obesity occurs not only long-term (10 years and over) weight loss of 35-40%, but also an important endocrine changes.

In recent years, it was discovered a number of signaling molecules produced by adipose tissue, whose physiological significance beyond the general metabolic aspects organism. The fat is therefore currently understood as an endocrine organ whose hormones modulate the function of many systems, including the skeleton. These hormones include the adipokines that modulate metabolism skeleton as at tissue level (Leptin, Adiponectin) and indirectly - by activation of neurohumoral hypothalamic centers - Leptin.

Studying endocrine interactions between adipose tissue and bone is a highly topical issue. This mutual communication is a homeostatic feedback system in which adipokines and molecules secreted by osteoblasts and osteoclasts are the connecting link active axes fat - bone tissue. However, the mechanisms of this axis remain largely unknown.

Conditions

• Grade III Obesity
• Type 2 Diabetes Mellitus

Interventions

PROCEDURE

Laparoscopic sleeve gastrectomy

Sleeve gastrectomy involves removing most of the stomach, limiting the amount of food the patient can eat.

PROCEDURE

Laparoscopic gastric plication

Laparoscopic gastric plication involves sewing one or more large folds in the stomach. During the laparoscopic gastric plication, the stomach volume is reduced about 70%, which makes the stomach able to hold less and helps the patient eat less.

PROCEDURE

Intragastric balloon

The introduction of the balloon is non-invasive as it is inserted endoscopically (down the oesophagus). The balloon is then filled inside the stomach with a dyed physiological solution, which reduces the volume of the stomach.

DEVICE

Intragastric balloon implantation

Intragastric balloons (End-Ball, Medsil) will be implanted in the patients with morbid obesity.

Sponsors & Collaborators

• University of Ostrava

  collaborator OTHER

• Vitkovice Hospital, Ostrava, Czech Republic

  collaborator UNKNOWN

• University Hospital Ostrava

  lead OTHER

Principal Investigators

• Marek Bužga, MSc., Ph.D. · Faculty of Medicine, Ostrava University, Ostrava

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

20 Years

Max Age

60 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2012-03-31

Primary Completion

2017-10-31

Completion

2017-12-31

Countries

• Czechia

Study Locations